nortriptyline has been researched along with Nicotine Addiction in 27 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The limited use of nortriptyline for smoking cessation is likely due to concerns about its serious adverse effects." | 8.87 | Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis. ( Chaiyakunapruk, N; Dhippayom, T; Jongchansittho, T, 2011) |
| "This article reviews the efficacy of nortriptyline for smoking cessation based on a meta-analysis of the Cochrane Library." | 8.82 | Nortriptyline for smoking cessation: a review. ( Hughes, JR; Lancaster, T; Stead, LF, 2005) |
| "Nicotine addiction has been identified as the primary contributor to continued widespread tobacco use worldwide." | 8.81 | Managing nicotine addiction. ( Hatsukami, DK; Kotlyar, M, 2002) |
| "In concurrence with clinical findings proposing alleviation of withdrawal states as a possible mechanism of bupropion and nortriptyline's smoking cessation action, both drugs were found to ameliorate somatic signs of nicotine withdrawal in rodents." | 7.74 | Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. ( Shoaib, M; Wing, VC, 2007) |
| "This study showed that nortriptyline significantly increases the smoking cessation rate in chronic smokers, as compared to the placebo group, without any significant side effects." | 5.10 | Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. ( da Costa, CL; Lourenço, MT; Younes, RN, 2002) |
| "The primary objective of this review was to assess the effectiveness of interventions to increase adherence to medications for smoking cessation, such as NRT, bupropion, nortriptyline and varenicline (and combination regimens)." | 4.91 | Interventions to increase adherence to medications for tobacco dependence. ( Aveyard, P; Farley, A; Hollands, GJ; Lindson-Hawley, N; McDermott, MS; Vogt, F, 2015) |
| " Smoking cessation has benefits at all ages but remains challenging for several reasons, among which are the complexities of nicotine addiction and limitations of available pharmacotherapies." | 4.90 | Emerging drugs for the treatment of tobacco dependence: 2014 update. ( Ebbert, JO; Elrashidi, MY, 2014) |
| "The limited use of nortriptyline for smoking cessation is likely due to concerns about its serious adverse effects." | 4.87 | Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis. ( Chaiyakunapruk, N; Dhippayom, T; Jongchansittho, T, 2011) |
| "This article reviews the efficacy of nortriptyline for smoking cessation based on a meta-analysis of the Cochrane Library." | 4.82 | Nortriptyline for smoking cessation: a review. ( Hughes, JR; Lancaster, T; Stead, LF, 2005) |
| "Nicotine addiction has been identified as the primary contributor to continued widespread tobacco use worldwide." | 4.81 | Managing nicotine addiction. ( Hatsukami, DK; Kotlyar, M, 2002) |
| " Smoking cessation is difficult due to nicotine addiction and withdrawal symptoms." | 3.76 | Current treatment options in smoking cessation. ( Bhat, A; Crain, D, 2010) |
| " There is strong evidence for the efficacy of the atypical antidepressant Bupropion as therapy for smoking cessation." | 3.75 | [Current and future medical drugs for smoking cessation]. ( Deissenrieder, F; Groneberg, D; Kusma, B; Mache, S; Quarcoo, D; Welte, T, 2009) |
| "In concurrence with clinical findings proposing alleviation of withdrawal states as a possible mechanism of bupropion and nortriptyline's smoking cessation action, both drugs were found to ameliorate somatic signs of nicotine withdrawal in rodents." | 3.74 | Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. ( Shoaib, M; Wing, VC, 2007) |
| "Pharmacological treatments for tobacco dependence, such as nicotine replacement therapy (NRT), have been shown to be safe and effective interventions for smoking cessation." | 2.61 | Interventions to increase adherence to medications for tobacco dependence. ( Aveyard, P; Farley, A; Hollands, GJ; Lindson, N; Naughton, F, 2019) |
| "Patients with COPD show higher nicotine dependence and seem to have greater difficulty in quitting smoking." | 2.47 | [Smoking in COPD]. ( Bernabé Barrios, MJ; Rodríguez Hermosa, JL; Santamaría Rodríguez, B; Zamarro García, C, 2011) |
| "Effective behavioral and pharmacologic treatments for smoking cessation are available." | 2.46 | Comparison of available treatments for tobacco addiction. ( Herman, AI; Sofuoglu, M, 2010) |
| "Optimization of NRT is of importance in COPD patients because they may be more nicotine dependent and have more difficulties to quit than smokers without COPD." | 2.45 | Therapeutic strategies to optimize the efficacy of nicotine replacement therapies. ( Berlin, I, 2009) |
| "Individuals with mental illness are particularly disadvantaged by their use of tobacco, spending as much as 40% of their income on cigarettes." | 2.44 | Use of smoking cessation therapies in individuals with psychiatric illness : an update for prescribers. ( Campbell, LA; Kisely, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 16 (59.26) | 29.6817 |
| 2010's | 10 (37.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hollands, GJ | 2 |
| Naughton, F | 1 |
| Farley, A | 2 |
| Lindson, N | 1 |
| Aveyard, P | 2 |
| van Eerd, EAM | 1 |
| van Schayck, OCP | 1 |
| Wesseling, G | 1 |
| Kotz, D | 1 |
| Chiamulera, C | 1 |
| West, RJ | 1 |
| Hartmann-Boyce, J | 1 |
| Hong, B | 1 |
| Livingstone-Banks, J | 1 |
| Wheat, H | 1 |
| Fanshawe, TR | 1 |
| Elrashidi, MY | 1 |
| Ebbert, JO | 1 |
| McDermott, MS | 1 |
| Lindson-Hawley, N | 1 |
| Vogt, F | 1 |
| Kusma, B | 1 |
| Mache, S | 1 |
| Deissenrieder, F | 1 |
| Quarcoo, D | 1 |
| Welte, T | 1 |
| Groneberg, D | 1 |
| Berlin, I | 1 |
| Crain, D | 1 |
| Bhat, A | 1 |
| Herman, AI | 1 |
| Sofuoglu, M | 1 |
| Dhippayom, T | 1 |
| Chaiyakunapruk, N | 1 |
| Jongchansittho, T | 1 |
| Zamarro García, C | 1 |
| Bernabé Barrios, MJ | 1 |
| Santamaría Rodríguez, B | 1 |
| Rodríguez Hermosa, JL | 1 |
| DeGraff, AC | 1 |
| da Costa, CL | 1 |
| Younes, RN | 1 |
| Lourenço, MT | 1 |
| Hall, SM | 2 |
| Humfleet, GL | 2 |
| Reus, VI | 2 |
| Muñoz, RF | 2 |
| Hartz, DT | 2 |
| Maude-Griffin, R | 1 |
| Kotlyar, M | 1 |
| Hatsukami, DK | 1 |
| Metcalfe, S | 1 |
| Moodie, P | 1 |
| McNee, W | 1 |
| Schroeder, SA | 1 |
| Hughes, JR | 1 |
| Stead, LF | 1 |
| Lancaster, T | 1 |
| Hill, A | 1 |
| Duquet, N | 1 |
| Cofta-Woerpel, L | 1 |
| Wright, KL | 1 |
| Wetter, DW | 1 |
| Frishman, WH | 1 |
| Wing, VC | 1 |
| Shoaib, M | 1 |
| Kisely, S | 1 |
| Campbell, LA | 1 |
| Benowitz, NL | 1 |
| Tsoh, JY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Helping People Adhere to Their Varenicline Treatment by Co-creating a Conversational Agent: A Feasibility Study[NCT05997901] | 40 participants (Anticipated) | Interventional | 2022-10-12 | Recruiting | |||
| "A Randomized Open-label, Superiority, Multicenter, Two-arm Intervention Study of the Effect of High-intensity vs. 'Low-intensity' Smoking Cessation Intervention in Active Smokers With COPD"[NCT04088942] | Phase 4 | 0 participants (Actual) | Interventional | 2023-07-01 | Withdrawn (stopped due to No funding) | ||
| A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 μg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation[NCT00633321] | Phase 2 | 522 participants (Anticipated) | Interventional | 2007-05-31 | Completed | ||
| Targeting Orexin to Treat Nicotine Dependence[NCT03999099] | Phase 1 | 45 participants (Anticipated) | Interventional | 2019-09-26 | Recruiting | ||
| An Innovative Digital Smoking Cessation Intervention for Low-Income Adults With Substance Use Disorder[NCT04419922] | 100 participants (Actual) | Observational | 2020-04-02 | Active, not recruiting | |||
| Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations[NCT01156610] | 706 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for nortriptyline and Nicotine Addiction
| Article | Year |
|---|---|
Interventions to increase adherence to medications for tobacco dependence.
Topics: Benzazepines; Bupropion; Drug Therapy, Combination; Humans; Medication Adherence; Nicotinic Agonists | 2019 |
Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation.
Topics: Behavior Therapy; Bupropion; Combined Modality Therapy; Female; Humans; Nicotinic Agonists; Nortript | 2019 |
Emerging drugs for the treatment of tobacco dependence: 2014 update.
Topics: Atomoxetine Hydrochloride; Benzazepines; Bupropion; Clinical Trials as Topic; Clonidine; Humans; Mec | 2014 |
Interventions to increase adherence to medications for tobacco dependence.
Topics: Benzazepines; Bupropion; Drug Therapy, Combination; Humans; Medication Adherence; Nicotinic Agonists | 2015 |
Therapeutic strategies to optimize the efficacy of nicotine replacement therapies.
Topics: Administration, Cutaneous; Administration, Oral; Antidepressive Agents, Second-Generation; Antidepre | 2009 |
Comparison of available treatments for tobacco addiction.
Topics: Behavior Therapy; Benzazepines; Bupropion; Humans; Nicotine; Nortriptyline; Quinoxalines; Smoking Ce | 2010 |
Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Dose-Response Relationship, Drug; Hu | 2011 |
[Smoking in COPD].
Topics: Benzazepines; Bupropion; Clonidine; Comorbidity; Disease Progression; Europe; Humans; Motivation; Ni | 2011 |
Managing nicotine addiction.
Topics: Administration, Inhalation; Adolescent; Adult; Antidepressive Agents, Tricyclic; Bupropion; Chewing | 2002 |
Nortriptyline for smoking cessation: a review.
Topics: Antidepressive Agents, Tricyclic; Evidence-Based Medicine; Humans; Nortriptyline; Randomized Control | 2005 |
A cost-effectiveness evaluation of single and combined smoking cessation interventions in Texas.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Bupropion; Clonidine; Cost-Benefit Analysis; Decis | 2006 |
[Quit smoking is not just a matter or will].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Humans; Nicot | 2006 |
Smoking cessation 3: multicomponent interventions.
Topics: Behavior Therapy; Bupropion; Clonidine; Combined Modality Therapy; Humans; Motivation; Nicotine; Nor | 2007 |
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations.
Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidi | 2007 |
Use of smoking cessation therapies in individuals with psychiatric illness : an update for prescribers.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Dopamine Uptake I | 2008 |
4 trials available for nortriptyline and Nicotine Addiction
| Article | Year |
|---|---|
Predictors of long-term smoking cessation in patients with COPD: results from a randomised controlled trial.
Topics: Aged; Female; Humans; Male; Middle Aged; Nortriptyline; Patient Participation; Prevalence; Pulmonary | 2017 |
Pharmacologic therapy for nicotine addiction.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Double-Blind | 2002 |
Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo.
Topics: Adult; Antidepressive Agents, Tricyclic; Double-Blind Method; Humans; Logistic Models; Middle Aged; | 2002 |
Psychological intervention and antidepressant treatment in smoking cessation.
Topics: Adult; Antidepressive Agents; Behavior, Addictive; Bupropion; Cognitive Behavioral Therapy; Combined | 2002 |
Psychological intervention and antidepressant treatment in smoking cessation.
Topics: Adult; Antidepressive Agents; Behavior, Addictive; Bupropion; Cognitive Behavioral Therapy; Combined | 2002 |
Psychological intervention and antidepressant treatment in smoking cessation.
Topics: Adult; Antidepressive Agents; Behavior, Addictive; Bupropion; Cognitive Behavioral Therapy; Combined | 2002 |
Psychological intervention and antidepressant treatment in smoking cessation.
Topics: Adult; Antidepressive Agents; Behavior, Addictive; Bupropion; Cognitive Behavioral Therapy; Combined | 2002 |
8 other studies available for nortriptyline and Nicotine Addiction
| Article | Year |
|---|---|
What role does dopamine really play in tobacco addiction?
Topics: Antidepressive Agents, Tricyclic; Bupropion; Dopamine; Humans; Nortriptyline; Nucleus Accumbens; Smo | 2018 |
[Current and future medical drugs for smoking cessation].
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Cannabi | 2009 |
Current treatment options in smoking cessation.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Clonidi | 2010 |
PHARMAC and tobacco control in New Zealand: two licensed funded options are already available.
Topics: Administration, Cutaneous; Bupropion; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines | 2005 |
Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal.
Topics: Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Dose-Response Relationship, Drug; | 2007 |
Treating tobacco addiction--nicotine or no nicotine?
Topics: Antidepressive Agents; Bupropion; Humans; Nicotine; Nortriptyline; Smoking Cessation; Substance With | 1997 |
Development of major depression after treatment for smoking cessation.
Topics: Adult; Central Nervous System Stimulants; Chewing Gum; Combined Modality Therapy; Comorbidity; Depre | 2000 |